Leptomeningeal Disease Clinical Trials

7 recruiting

Leptomeningeal Disease Trials at a Glance

9 actively recruiting trials for leptomeningeal disease are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in New York, Tübingen, and München. Lead sponsors running leptomeningeal disease studies include H. Lee Moffitt Cancer Center and Research Institute, University Hospital Tuebingen, and Sunnybrook Health Sciences Centre.

Browse leptomeningeal disease trials by phase

Treatments under study

About Leptomeningeal Disease Clinical Trials

Looking for clinical trials for Leptomeningeal Disease? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leptomeningeal Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leptomeningeal Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Non Interventional German Leptomeningeal Disease Register

Leptomeningeal DiseaseMeningeal Neoplasms
University Hospital Tuebingen50 enrolled7 locationsNCT06146010
Recruiting
Phase 1

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute18 enrolled3 locationsNCT05809752
Recruiting
Phase 2

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Metastatic Breast CancerLeptomeningeal Disease
Wake Forest University Health Sciences16 enrolled3 locationsNCT02422641
Recruiting
Not Applicable

CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases

Brain MetastasasesSolid Tumor MalignanciesLeptomeningeal Disease (LMD)
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07476781
Recruiting
Phase 1Phase 2

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

HER2-positive Breast CancerLeptomeningeal DiseaseLeptomeningeal Metastasis
H. Lee Moffitt Cancer Center and Research Institute39 enrolled2 locationsNCT04588545
Recruiting
Phase 1

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Recurrent Glioblastoma MultiformePrimary Glioblastoma MultiformeBrain Neoplasms, Malignant+1 more
AstraZeneca180 enrolled12 locationsNCT03423628
Recruiting
Phase 2

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

HER2-positive Metastatic Breast CancerLeptomeningeal DiseaseLeptomeningeal Metastasis
UNICANCER30 enrolled11 locationsNCT05800275
Recruiting
Phase 1

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

Leptomeningeal Disease
University Hospital Tuebingen46 enrolled9 locationsNCT05112549
Recruiting

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis

Leptomeningeal DiseaseLeptomeningeal MetastasisLeptomeningeal Neoplasms+1 more
University of Zurich200 enrolled3 locationsNCT06417710